Literature DB >> 22892943

[Psychotherapeutic approaches for patients with somatoform disorders].

J M Gottschalk1, W Rief.   

Abstract

Patients with somatoform symptoms are considered to be difficult to treat. Clinical studies on treatment of this condition are underrepresented compared to other mental and psychosomatic disorders. Cognitive-behavioral treatment for patients with somatoform symptoms was found to have a significant effect; additionally, some evidence of recently published findings supports psychodynamic therapy. This report provides information on how to effectively deal with those patients. Furthermore it describes transtherapeutic targets and explains three therapeutic phases: establishing a therapeutic relationship, developing a model of the disorder and establishing coping strategies. As a last point a cognitive-behavioral treatment study, a psychodynamically-oriented study, a group intervention study and a new approach, a combination of cognitive-behavioral therapy and emotion regulation training, are presented.

Entities:  

Mesh:

Year:  2012        PMID: 22892943     DOI: 10.1007/s00115-011-3445-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  35 in total

1.  Brief psychodynamic interpersonal psychotherapy for patients with multisomatoform disorder: randomised controlled trial.

Authors:  H Sattel; C Lahmann; H Gündel; E Guthrie; J Kruse; M Noll-Hussong; C Ohmann; J Ronel; M Sack; N Sauer; G Schneider; P Henningsen
Journal:  Br J Psychiatry       Date:  2011-11-10       Impact factor: 9.319

2.  Efficacy of short-term psychotherapy for multiple medically unexplained physical symptoms: a meta-analysis.

Authors:  Maria Kleinstäuber; Michael Witthöft; Wolfgang Hiller
Journal:  Clin Psychol Rev       Date:  2010-09-16

3.  Effectiveness of strategies for informing, educating, and involving patients.

Authors:  Angela Coulter; Jo Ellins
Journal:  BMJ       Date:  2007-07-07

4.  A two-year follow-up study of patients with somatoform disorders.

Authors:  W Rief; W Hiller; E Geissner; M M Fichter
Journal:  Psychosomatics       Date:  1995 Jul-Aug       Impact factor: 2.386

5.  Cognitive-behavioral therapy for somatization disorder: a randomized controlled trial.

Authors:  Lesley A Allen; Robert L Woolfolk; Javier I Escobar; Michael A Gara; Robert M Hamer
Journal:  Arch Intern Med       Date:  2006-07-24

6.  Effectiveness of a time-limited cognitive behavior therapy type intervention among primary care patients with medically unexplained symptoms.

Authors:  Javier I Escobar; Michael A Gara; Angelica M Diaz-Martinez; Alejandro Interian; Melissa Warman; Lesley A Allen; Robert L Woolfolk; Eric Jahn; Denise Rodgers
Journal:  Ann Fam Med       Date:  2007 Jul-Aug       Impact factor: 5.166

7.  Patients whom neurologists find difficult to help.

Authors:  A J Carson; J Stone; C Warlow; M Sharpe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

Review 8.  Reattribution reconsidered: narrative review and reflections on an educational intervention for medically unexplained symptoms in primary care settings.

Authors:  Linda Gask; Christopher Dowrick; Peter Salmon; Sarah Peters; Richard Morriss
Journal:  J Psychosom Res       Date:  2011-06-28       Impact factor: 3.006

9.  Cognitive-behavioural therapy v. structured care for medically unexplained symptoms: randomised controlled trial.

Authors:  A Sumathipala; S Siribaddana; M R N Abeysingha; P De Silva; M Dewey; M Prince; A H Mann
Journal:  Br J Psychiatry       Date:  2008-07       Impact factor: 9.319

10.  Analyzing the problems in managing patients with medically unexplained symptoms.

Authors:  Winfried Rief
Journal:  J Gen Intern Med       Date:  2007-05       Impact factor: 5.128

View more
  1 in total

1.  Non-specific, functional, and somatoform bodily complaints.

Authors:  Rainer Schaefert; Constanze Hausteiner-Wiehle; Winfried Häuser; Joram Ronel; Markus Herrmann; Peter Henningsen
Journal:  Dtsch Arztebl Int       Date:  2012-11-23       Impact factor: 5.594

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.